GlassScriptPhysician profile
Gerald M Barber
NPI 1992704969
$14,028.28
in general payments reported to CMS, 2019-2025
50 companies · $953 in 2025
The $953 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,255 · 2020: $1,848 · 2021: $2,449 · 2022: $2,166 · 2023: $2,085 · 2024: $2,274 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,311.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,526.96 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,495.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,267.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,176.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,148.13 | 2019-2025 | Jardiance, Ofev, Glyxambi |
| Lilly USA, LLC | $1,022.73 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $661.27 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $608.04 | 2019-2023 | |
| Abbott Laboratories | $491.47 | 2021-2024 | Infinity, Freestyle Libre 3, Proclaim |
| Amgen INC. | $452.78 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $402.56 | 2019-2020 | |
| Pfizer INC. | $383.08 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $327.61 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $297.34 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $284.48 | 2020-2025 | Nexletol |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.